MeSH Browser

MeSH Heading: Spironolactone
Tree Number(s): D02.540.679; D04.210.500.745.745.855
Unique ID: D013148
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D013148
Scope Note: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
Entry Term(s): Aldactone; Aldactone A; Aquareduct; Duraspiron; Espironolactona Alter; Espironolactona Mundogen; Flumach; Frumikal; Jenaspiron; Novo-Spiroton; Practon; SC-9420; Spiractin; Spiro L.U.T.; Spiro Von Ct; Spirobeta; Spirogamma; Spirolactone; Spirolang; Spirono-Isis; Spironone; Spirospare; Veroshpiron; Verospiron; Verospirone
Pharm Action: Mineralocorticoid Receptor Antagonists
Diuretics
Registry Numbers: 27O7W4T232; 0
Related Numbers: 52-01-7
CAS Type 1 Name: Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, gamma-lactone, (7alpha,17alpha)-
NLM Classification #: QV 160
Date Established: 1966/01/01
Date of Entry: 1999/01/01
Revision Date: 2017/05/24

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analogs & derivatives (AA)

analysis (AN)

antagonists & inhibitors (AI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

economics (EC)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

urine (UR)

Concept UI: M0020352
Registry Numbers: 27O7W4T232
Related Numbers: 52-01-7
Scope Note: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
Terms: Spironolactone Preferred Term
Term UI T038653
Date01/01/1999
LexicalTag NON
ThesaurusID; Verospirone
Term UI T038654
Date02/10/1981
LexicalTag NON
ThesaurusID UNK (19XX); Spirolactone
Term UI T038655
Date12/30/1976
LexicalTag NON
ThesaurusID UNK (19XX); Veroshpiron
Term UI T038656
Date06/07/1989
LexicalTag NON
ThesaurusID NLM (1990)